Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells

@inproceedings{Yi2013TargetingMP,
  title={Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells},
  author={Yong Weon Yi and Hyo Jin Kang and Hee Jeong Kim and Yali Kong and Milton L. Brown and In‐kyoung Bae},
  booktitle={Oncotarget},
  year={2013}
}
Many types of mutations in tumor suppressor p53 are oncogenic through gain-of-function. Therefore, targeting mutant p53 (mtp53) is a promising therapeutic approach to fight against many types of cancers. We report here a small molecule compound YK-3-237 that reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells carrying mtp53. YK-3-237 activates SIRT1 enzyme activities in vitro and deacetylation of both mtp53 in a SIRT1-dependent… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS, ESTIMATED 47% COVERAGE

66 Citations

01020'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 66 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

Similar Papers

Loading similar papers…